A
Adriana D. Corben
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 51
Citations - 1895
Adriana D. Corben is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 20, co-authored 49 publications receiving 1457 citations. Previous affiliations of Adriana D. Corben include Harvard University & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
The epichaperome is an integrated chaperome network that facilitates tumour survival
Anna Rodina,Tai Wang,Pengrong Yan,Erica DaGama Gomes,Mark Dunphy,Nagavarakishore Pillarsetty,John Koren,John F. Gerecitano,Tony Taldone,Hongliang Zong,Eloisi Caldas-Lopes,Mary L. Alpaugh,Adriana D. Corben,Matthew Riolo,Brad Beattie,Christina Pressl,Radu I Peter,Chao Xu,Robert Trondl,Hardik J. Patel,Fumiko Shimizu,Alexander Bolaender,Chenghua Yang,Palak Panchal,Mohammad F. Farooq,Sarah Kishinevsky,Shanu Modi,Oscar Lin,Feixia Chu,Sujata Patil,Hediye Erdjument-Bromage,Pat Zanzonico,Clifford A. Hudis,Lorenz Studer,Gail J. Roboz,Ethel Cesarman,Leandro Cerchietti,Ross L. Levine,Ari Melnick,Steven M. Larson,Jason S. Lewis,Monica L. Guzman,Gabriela Chiosis,Gabriela Chiosis +43 more
TL;DR: It is found that under conditions of stress, such as malignant transformation fuelled by MYC, the chaperome becomes biochemically ‘rewired’ to form a network of stable, survival-facilitating, high-molecular-weight complexes.
Journal ArticleDOI
Antitumorigenic potential of STAT3 alternative splicing modulation
Francesca Zammarchi,Elisa de Stanchina,Eirini Bournazou,Teerawit Supakorndej,Kathryn Martires,Elyn Riedel,Adriana D. Corben,Jacqueline Bromberg,Luca Cartegni +8 more
TL;DR: Similar in vivo redirection of STAT3 alternative splicing leads to tumor regression in a xenograft cancer model, demonstrating how pharmacological manipulation of a single key splicing event can manifest powerful antitumorigenic properties and validating endogenous splicing reprogramming as an effective cancer therapeutic approach.
Journal ArticleDOI
Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience.
Clare Bryce,Zachary Grimes,Elisabet Pujadas,Sadhna Ahuja,Mary Beth Beasley,Randy A. Albrecht,Tahyna Hernandez,Aryeh Stock,Zhen Zhao,Mohamed Rizwan AlRasheed,Joyce Chen,Li Li,Diane Wang,Adriana D. Corben,G. Kenneth Haines,William H. Westra,Melissa Umphlett,Ronald E. Gordon,Jason Reidy,Bruce Petersen,Fadi Salem,Maria Isabel Fiel,Siraj M. El Jamal,Nadejda M. Tsankova,Jane Houldsworth,Zarmeen Mussa,Brandon Veremis,Emilia Mia Sordillo,Melissa R. Gitman,Michael D. Nowak,Rachel Brody,Noam Harpaz,Miriam Merad,Sacha Gnjatic,Wen-Chun Liu,Michael Schotsaert,Lisa Miorin,Teresa A. Aydillo Gomez,Irene Ramos-Lopez,Adolfo García-Sastre,Ryan Donnelly,Patricia Seigler,Calvin Keys,Jennifer Cameron,Isaiah Moultrie,Kae Lynn Washington,Jacquelyn D. Treatman,Robert Sebra,Jeffrey S. Jhang,Adolfo Firpo,John A. Lednicky,Alberto Paniz-Mondolfi,Carlos Cordon-Cardo,Mary Fowkes +53 more
TL;DR: The first 100 COVID-19-positive autopsies performed at the Mount Sinai Hospital in New York City revealed large pulmonary emboli in six cases and diffuse alveolar damage was present in over 90% of cases as mentioned in this paper.
Journal ArticleDOI
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.
Komal Jhaveri,Stefan O. Ochiana,Mark Dunphy,John F. Gerecitano,Adriana D. Corben,Radu I Peter,Yelena Y. Janjigian,Erica M. Gomes-DaGama,John Koren,Shanu Modi,Gabriela Chiosis +10 more
TL;DR: In this article, the authors highlight the current status of the second-generation HSP90 inhibitors in clinical development and highlight the lessons learned from the completed clinical trials of first-and secondgeneration inhibitors and describe various assays attempting to serve for a more rational implementation of these agents to cancer treatment.
Journal ArticleDOI
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
Gary A. Ulaner,David M. Hyman,Dara S. Ross,Adriana D. Corben,Sarat Chandarlapaty,Shari Goldfarb,Heather L. McArthur,Joseph P. Erinjeri,Stephen B. Solomon,Hartmuth C. Kolb,Serge K. Lyashchenko,Jason S. Lewis,Jorge A. Carrasquillo +12 more
TL;DR: A proof-of-concept study demonstrated that 89Zr-trastuzumab PET/CT detects unsuspected HER2-positive metastases in patients with Her2-negative primary breast cancer, which is a proof of the concept that her2-targeted imaging can identify additional candidates for HER2 -targeted therapy.